143 related articles for article (PubMed ID: 35489202)
21. The essential role for aromatic cluster in the β3 adrenergic receptor.
Cai HY; Xu ZJ; Tang J; Sun Y; Chen KX; Wang HY; Zhu WL
Acta Pharmacol Sin; 2012 Aug; 33(8):1062-8. PubMed ID: 22728712
[TBL] [Abstract][Full Text] [Related]
22. β
Kawaguchi S; Okada M; Ijiri E; Koga D; Watanabe T; Hayashi K; Kashiwagi Y; Fujita S; Hasebe N
Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H283-H294. PubMed ID: 31834837
[TBL] [Abstract][Full Text] [Related]
23. An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant.
Tasler S; Baumgartner R; Behr-Roussel D; Oger-Roussel S; Gorny D; Giuliano F; Ney P
Eur J Pharm Sci; 2012 Aug; 46(5):381-7. PubMed ID: 22430195
[TBL] [Abstract][Full Text] [Related]
24. CNS β
Richard JE; López-Ferreras L; Chanclón B; Eerola K; Micallef P; Skibicka KP; Wernstedt Asterholm I
Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E344-E358. PubMed ID: 28588096
[TBL] [Abstract][Full Text] [Related]
25. Do β-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder?
Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 2014 Mar; 387(3):215-24. PubMed ID: 24213882
[TBL] [Abstract][Full Text] [Related]
26. Enhanced cAMP response of naturally occurring mutant of human beta3-adrenergic receptor.
Isogaya M; Nagao T; Kurose H
Jpn J Pharmacol; 2002 Mar; 88(3):314-8. PubMed ID: 11949887
[TBL] [Abstract][Full Text] [Related]
27. Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health.
Grudell AB; Camilleri M; Jensen KL; Foxx-Orenstein AE; Burton DD; Ryks MD; Baxter KL; Cox DS; Dukes GE; Kelleher DL; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2008 May; 294(5):G1114-9. PubMed ID: 18372395
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of the β3-adrenergic receptor agonist solabegron and analogous N-(2-ethylamino)-β-amino alcohols from O-acylated cyanohydrins - expanding the scope of minor enantiomer recycling.
Hertzberg R; Monreal Santiago G; Moberg C
J Org Chem; 2015 Mar; 80(5):2937-41. PubMed ID: 25689345
[TBL] [Abstract][Full Text] [Related]
29. The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism.
Soeder KJ; Snedden SK; Cao W; Della Rocca GJ; Daniel KW; Luttrell LM; Collins S
J Biol Chem; 1999 Apr; 274(17):12017-22. PubMed ID: 10207024
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β
Aizawa N; Fujimori Y; Nakanishi O; Hayashi T; Goi Y; Kobayashi JI; Fujita T
Eur J Pharmacol; 2021 May; 899():173995. PubMed ID: 33675781
[TBL] [Abstract][Full Text] [Related]
31. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
Andersson KE; Martin N; Nitti V
J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
[TBL] [Abstract][Full Text] [Related]
32. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
Thiagamoorthy G; Giarenis I; Cardozo L
Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
[TBL] [Abstract][Full Text] [Related]
33. Requirement of vimentin filament assembly for beta3-adrenergic receptor activation of ERK MAP kinase and lipolysis.
Kumar N; Robidoux J; Daniel KW; Guzman G; Floering LM; Collins S
J Biol Chem; 2007 Mar; 282(12):9244-50. PubMed ID: 17251187
[TBL] [Abstract][Full Text] [Related]
34. Distinct Conformations of Mirabegron Determined by MicroED.
Lin J; Unge J; Gonen T
Adv Sci (Weinh); 2023 Dec; 10(34):e2304476. PubMed ID: 37847906
[TBL] [Abstract][Full Text] [Related]
35. Discovery of benzamides as potent human β3 adrenergic receptor agonists.
Zhu C; Kar NF; Li B; Costa M; Dingley KH; Di Salvo J; Ha SN; Hurley AL; Li X; Miller RR; Salituro GM; Struthers M; Weber AE; Hale JJ; Edmondson SD
Bioorg Med Chem Lett; 2016 Jan; 26(1):55-9. PubMed ID: 26590100
[TBL] [Abstract][Full Text] [Related]
36. β3-agonist therapy: a new advance in the management of overactive bladder?
Chapple CR
Eur Urol; 2012 Nov; 62(5):841-2. PubMed ID: 22901985
[No Abstract] [Full Text] [Related]
37. Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder.
Rouget C; Rekik M; Camparo P; Botto H; Rischmann P; Lluel P; Palea S; Westfall TD
Pharmacol Res; 2014 Feb; 80():14-20. PubMed ID: 24378642
[TBL] [Abstract][Full Text] [Related]
38. Mirabegron: potential off target effects and uses beyond the bladder.
Dehvari N; da Silva Junior ED; Bengtsson T; Hutchinson DS
Br J Pharmacol; 2018 Nov; 175(21):4072-4082. PubMed ID: 29243229
[TBL] [Abstract][Full Text] [Related]
39. Mirabegron, a β
Mendes-Silvério CB; Alexandre EM; Lescano CH; Antunes E; Mónica FZ
Eur J Pharmacol; 2018 Jun; 829():79-84. PubMed ID: 29654782
[TBL] [Abstract][Full Text] [Related]
40. Molecular and functional characteristics of β3-adrenoceptors in late pregnant mouse uterus: a comparison with β2-adrenoceptors.
Parida S; Uttam Singh T; Ravi Prakash V; Mishra SK
Eur J Pharmacol; 2013 Jan; 700(1-3):74-9. PubMed ID: 23219791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
